Review Article

Outpatient Management of Cirrhosis: A Narrative Review

Authors: Ronnie E. Mathews, Jr, MD, Brendan M. McGuire, MD, Carlos A. Estrada, MD, MS

Abstract

Abstract:Cirrhosis is the 12th leading cause of death in the United States. Individuals with cirrhosis are at risk for many potential complications. Complications can be managed or detected early with proper outpatient management. The most lethal of these complications is bleeding esophageal varices. All patients with cirrhosis should be screened for the presence of varices and treated when indicated. The most common complication seen in these patients is ascites. Ascites can be treated with dietary modifications and a diuretic regimen. Other potential complications include spontaneous bacterial peritonitis, hepatocellular carcinoma, hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome. The outpatient management of these complications will be discussed in this paper, along with the use of vaccinations, educating patients about the avoidance of hepatotoxic drugs, and when to refer a patient for liver transplant.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Kochanek KD, Murphy SL, Anderson RN, et al. Deaths: final data for 2002. Natl Vital Stat Rep2004;53:1–115.
 
2. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2005;158:1–199.
 
3. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472.
 
4. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992;21:149–161.
 
5. Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis.Gastroenterology 1982;82:968–973.
 
6. de Dombal FT, Clarke JR, Clamp SE, et al. Prognostic factors in upper GI bleeding. Endoscopy1986;18 (Suppl 2):6–10.
 
7. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology1981;80:800–809.
 
8. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475–505.
 
9. Lowe RC, Grace ND. Primary prophylaxis of variceal hemorrhage. Clin Liver Dis 2001;5:665–676.
 
10. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study: the North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. N Engl J Med 1988;319:983–989.
 
11. Arguedas MR, Heudebert GR, Eloubeidi MA, et al. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol 2002;97:2441–2452.
 
12. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532–1538.
 
13. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65–72.
 
14. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997;25:63–70.
 
15. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology2000;32:461–465.
 
16. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors.Hepatology 1987;7:122–128.
 
17. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215–220.
 
18. McGuire BM, Bloomer JR. Complications of cirrhosis: why they occur and what to do about them.Postgrad Med 1998;103:209–12, 217–8, 223–224.
 
19. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468–475.
 
20. Rosemurgy AS, Zervos EE, Clark WC, et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004;239:883–891.
 
21. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171–175.
 
22. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document: International Ascites Club. J Hepatol 2000;32:142–153.
 
23. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27–31.
 
24. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716–724.
 
25. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817–823.
 
26. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675–680.
 
27. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients: Cancer of the Liver Italian Program.Hepatology 2001;34:529–534.
 
28. Farinati F, Rinaldi M, Gianni S, et al. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89:2266–2273.
 
29. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181–200.
 
30. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61–66.
 
31. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002;36:S84–S92.
 
32. Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis2001;5:123–144.
 
33. Arguedas MR, Chen VK, Eloubeidi MA, et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679–690.
 
34. Arguedas MR. Screening for hepatocellular carcinoma: why, when, how? Curr Gastroenterol Rep2003;5:57–62.
 
35. Quero JC, Hartmann IJ, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis.Hepatology 1996;24:556–560.
 
36. Sood GK, Sarin SK, Mahaptra J, et al. Comparative efficacy of psychometric tests in detection of subclinical hepatic encephalopathy in nonalcoholic cirrhotics: search for a rational approach. Am J Gastroenterol 1989;84:156–159.
 
37. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473–479.
 
38. Plauth M, Merli M, Kondrup J. Management of hepatic encephalopathy. N Engl J Med1997;337:1921–1922.
 
39. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38–43.
 
40. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201–205.
 
41. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404–1406.
 
42. Arguedas MR, Johnson A, Eloubeidi MA, et al. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001;34:28–31.
 
43. Carson JL, Willett LR Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs 1993;46 (Suppl 1):243–248.
 
44. Riley TR III, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998;93:1563–1565.
 
45. Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med 1999;14:699–704.
 
46. Tong W, Hurley S, Hayashi PH. Reconsidering hepatorenal syndrome: throw in the towel? Not so fast¡ Postgrad Med 2004;116:15–6, 21–24.
 
47. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229–236.
 
48. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690–1697.
 
49. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients.Transplantation 1991;51:428–430.
 
50. Abrams GA, Jaffe CC, Hoffer PB, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995;109:1283–1288.
 
51. Schenk P, Schoniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003;125:1042–1052.
 
52. Arguedas MR, Abrams GA, Krowka MJ, et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology2003;37:192–197.
 
53. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5:307–313.
 
54. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470.
 
55. Murray KF, Carithers RL Jr. ASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005;41:1407–1432.